Emalex Lands $250M for Phase-3 Trial of Tourette’s Drug

A new drug treatment for Tourette syndrome from Emalex Biosciences, a company known for developing solutions for rare and orphan neurological conditions as well as central nervous system disorders, is making waves in the healthcare investment world based on its stellar results from targeting a different part of the central nervous system than other approved drugs on the market...